^(131)I治疗对Graves病眼病患者血清白细胞介素-1β水平的影响  

Effect of Iodine-131Treatment on Serum IL-1β Level in Patients with Graves' Ophthalmopathy

作　　者：方文珠[1] 林敏华[1] 罗章伟[1] 陆进[1] 凌彩霞[1] 廖书鸿[1] 

机构地区：[1]右江民族医学院附属医院核医学科,广西百色533000

出　　处：《中国慢性病预防与控制》2011年第2期194-195,共2页Chinese Journal of Prevention and Control of Chronic Diseases

基　　金：广西壮族自治区卫生厅科研基金(z2007358)

摘　　要：目的探讨131I治疗后Graves病眼病(GO)患者血清IL-1β水平的改变。方法根据临床活动度评分(CAS)标准确定76例GO患者的病变活动度及严重程度,并将其分为轻(30例)、中(27例)、重(19例)三组;Graves病无突眼组(NGO)50例;健康对照组30例。采用131I对GO和NGO组进行正规治疗。90 d后采用RIA测定各组血清IL-1β水平并进行促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)的检测。结果 GO各组治疗前IL-1β均高于NGO组及健康对照组(P<0.05),治疗90 d后GO患者各组的血清IL-1β水平较治疗前明显下降,且与CAS呈正相关(r=0.258,P<0.05)。结论 131I治疗能有效抑制GO患者自身免疫;血清IL-1β水平可作为预测GO活动度的指标。Objective To study the changes of serum IL-1β levels in patients with Graves＇ ophthalmopathy （GO） treated with Iodine-1β. Methods The severity and activity of GO were assessed by the clinical activity score （CAS）, then they were divided into four groups： group A was mild （n=30）, group B was moderate （n：27）, group C was severe （n=19）;50 patients with Graves disease （GD） but not complicated with GO was as NGO group and 30 health people were as the controls （NC group）. GO and NGO groups were regular cured with 1hi. After 90d treatment, the serum levels of interleukin-1β （IL-1β） were measured by radioimmunoassay and serum levels of FT3, FF4 and TSH were also measured. Results Before the treatment, the IL-1β level in GO patients was significantly higher than those in the NGO and NC group （P〈0.05）; after iodine-1β treatment, the serum level of IL-1β decreased. The level of IL-1β was related to CAS in GO patients （r=0.258, P〈0.05）. Conclusions Suceessful iodine-1β therapy would effectively suppress the autoimmune status in Graves＇ ophthalmopathy patients, the results suggest that serum levels of IL-1β could be an indicator for predicting the activity of GO.

关 键 词：GRAVES眼病 白细胞介素-1Β 活动度 131↑碘治疗 

分 类 号：R581[医药卫生—内分泌]